ERBB2 and breast cancer: In particular, a vaccine formulation combining the HER2 ICD with the heat shock complex HSP110 has been shown to elicit strong antitumor immune responses and effectively inhibit spontaneous mammary tumors in a rat neu transgenic mouse model [293].